Grifols (GRFS) Stock Analysis & Forecast

Nov 13 close

$8.69−0.11 (−1.3%)

Gekko Brief

AI summaryNov 9 close

Grifols moved this week on third-quarter results and dividend news. The company reported Q3 2026 results alongside an interim dividend of €0.15 per share, which Gekko's summary describes as stabilizing investor sentiment and lifting the share price. Separately, Wall Street Zen and JPMorgan Chase & Co. lowered their rating and price targets on the stock, even as another commentary pointed to revenue above €2 billion for the quarter, EBITDA up 10%, net profit up 28%, and leverage below 4x, with management reiterating full-year targets despite continued weakness in China's albumin market.

Shares closed at $8.69, up 3.1% on the day, sitting between the 50-day average of $7.67 and the 200-day average of $7.99. The GekkoIndex reads 41.2, placing the stock in the Distribution zone. Price remains 29.9% below Gekko Fair Value of $12.39.

Over the next 20 trading days, the next earnings date falls on 4 March 2027, well outside this window. No insider, Congress or unusual options activity appears in their respective 90-day and 30-day windows, and there are no billionaire or trailblazer holders recorded. Seasonality over this stretch has averaged -0.7% across 5 years, rising in 3 of them. The sole covered analyst holds a hold rating, with a consensus target of $10.37 implying 19.3% upside. The gap to Gekko Fair Value bears watching given the Distribution reading.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Grifols price vs fair value

▲$11.92$8.69Nov ’25May ’26Nov ’26
Close $8.69200-day averageGekko Fair Value $11.92

Grifols quick facts

Market cap
$7.35B
P/E ratio
10.5
Forward P/E
7.3
EPS, TTM
$0.83
Revenue, TTM
$7.60B
Profit margin
6.4%
Dividend yield
—
Beta
1.13
Volume
312,662 avg 752,397
1-year return
0.0%
Typical daily move
±3.1%
Typical 20-day move
±8.7%
50-day average
$7.75
200-day average
$7.98
Next earnings
Mar 4
Shares outstanding
258.2M
52-week range
$6.96$9.77

Grifols swing-trade checklist

Grifols scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

2 supportive2 mixed1 headwind

  • Trendmixed

    Averages disagree

    Close $8.69 sits between the 50-day ($7.75) and 200-day ($7.98) averages, or the averages disagree.

    See the chart
  • GekkoIndexmixed

    45.9, Neutral

    Reading 45.9 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    27.1% below

    Price is 27.1% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 109 days

    Next report Mar 4, 2027, 109 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −2.4% on average

    From this point in the calendar, the next 20 trading days averaged −2.4% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Grifols stock chart and price history

Grifols closed at $8.69 on Nov 13, 2026, 0.0% over the past year, inside a 52-week range of $6.96 to $9.77.

Close50-day average200-day averageVolume
Grifols share price, past year, with 50-day and 200-day moving averages and volume$7$8$9DecJan 2026FebMarAprMayJunJulAugSepOctNov8.69

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+15.3%
3 months
+11.8%
6 months
+13.4%
1 year
0.0%
The full GRFS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GRFS in Gekko

Follow Grifols through every session

Put GRFS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track GRFS in GekkoFree for 7 days. No credit card required.

About Grifols

Grifols works mainly with human plasma, turning it into medicines used to manage serious and long-term illnesses. Among its most recognized products are immunoglobulins, alpha-1 antitrypsin, albumin and clotting factors, which help address conditions like hemophilia and problems with the immune system. The company also supplies hospitals with pharmaceutical items that are not biological in nature, along with medical devices, nutrition products for clinical settings and intravenous solutions.

Its business spans several distinct areas. One focuses on researching and marketing plasma-based treatments, another handles hospital-related supplies, and a further division builds diagnostic tools used at every stage of patient care, from early screening through to tracking treatment progress. A separate arm distributes biological materials needed for scientific research, clinical testing and the production of drugs and diagnostic goods. Buyers of these products include hospitals, blood banks, wholesalers, distributors, purchasing groups and both public and private health systems, and the company also works with Mondragon under a shared technology arrangement.

Grifols traces its origins to 1940 and runs its operations from Barcelona, Spain. Its stock can be found under the ticker GRFS.

Sector
Health technology
Website
grifols.com

Grifols GekkoIndex: the smart money zone

Grifols’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 45.9, in the Neutral zone, up 2.4 points over five sessions.

010045.9Neutral

Up 2.4 points over five sessions, from the Distribution zone.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying24+4.5%+5.6%+7.9%+10.4%
Accumulation240+0.4%+1.2%+2.8%+2.1%
Neutral (current zone)337+0.2%+0.3%+0.1%+1.4%
Distribution54−0.5%−1.6%−4.3%−0.3%
Selling0Not available

Average GRFS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the GRFS price, zone by zone.Track GRFS in Gekko

Is Grifols stock overvalued? Gekko Fair Value

Grifols trades 27.1% below Gekko Fair Value of $11.92, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Grifols shares are worth, recalculated every trading day.

$11.92

Gekko Fair Value, Nov 14, 2026

27.1% Undervalued

At the end of Aug 2026 the price was 45.5% below the estimate.

Gekko Fair ValueShare price, month end
$12$9Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open GRFS in Gekko

Grifols insider and Congress trading

No open-market insider purchases were filed for Grifols, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for GRFS in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every GRFS insider filing, plotted on the chart in Gekko.Open GRFS in Gekko

Congress trades last 90 days

No trades in GRFS were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for GRFS, plotted on the chart in Gekko.Open GRFS in Gekko

Hedge funds and billionaires quarter ended Dec 31

0of the funds Gekko tracks hold GRFS.

0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko

Grifols earnings: next date and track record

Grifols reports on Mar 4, 2027 (109 days away), and beat the EPS estimate in 1 of its last 8 reports.

1 of 8reports beat the EPS estimate
±5%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

−3.1%Jul ’24+4.9%Nov ’24−3.2%Mar ’25+10.7%May ’25+4.0%Jul ’25−8.5%Nov ’25−1.6%Feb ’26−3.7%May ’26

Last earnings call, May 7, 2026 AI summary

What they said
Grifols reported Q1 2026 revenue of EUR 1.7 billion, up 3.3% at constant currency. Adjusted EBITDA reached EUR 404 million at constant currency with margins broadly stable year-on-year. Biopharma grew nearly 7% at constant currency, driven by double-digit IG franchise growth. Leverage stood at 4.3x, and free cash flow improved EUR 30 million. Egypt EMA approval strengthens plasma diversification and reduces cost per liter.
Guidance
Grifols reaffirmed full-year 2026 guidance targeting adjusted EBITDA margins of at least 25%, 5%-9% adjusted EBITDA growth at constant currency, and free cash flow of EUR 500-575 million. Management expressed confidence results are tracking in line with expectations.
ReportedEPSSurpriseRevenueSurpriseMove
May 7, 2026$0.13
est $0.15
−15.0%$2.00B
est $2.03B
−1.4%−3.7%
Feb 26, 2026$0.29
est $0.29
+0.8%$2.34B
est $2.34B
−0.2%−1.6%
Nov 4, 2025$0.21
est $0.24
−12.8%$2.14B
est $2.15B
−0.6%−8.5%
Jul 28, 2025$0.22
est $0.28
−21.4%$2.17B
est $2.20B
−1.2%+4.0%
May 12, 2025$0.09
est $0.16
−43.9%$1.99B
est $1.96B
+1.7%+10.7%
Mar 6, 2025$0.11
est $0.23
−52.7%——−3.2%
Nov 7, 2024$0.17
est $0.24
−29.2%——+4.9%
Jul 30, 2024$0.15
est $0.23
−34.8%——−3.1%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Grifols stock forecast and analyst price targets

Analysts’ average 12-month price target for Grifols is $10.37, +19.3% from the last close, from 1 firm rating the stock in the last 90 days.

$10.37consensus 12-month target, +19.3% from the last close
Buy0
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 1 firm.

Latest analyst actions

DateFirmRatingTargetvs price
Oct 26J.P. MorganHold, reiterated$9+3.6%
+0.1%average 20-day move after past Neutral readings
−2.4%average move over the next 20 trading days in the last 5 years
±3.1%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Grifols seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Grifols averaged −2.4% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−10.1%2021−1.4%2022+12.1%2023−23.2%2024+3.7%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−2.4%1 of 5
Next 10 trading days−4.2%2 of 5
Next 15 trading days−4.3%2 of 5
Next 20 trading days−2.4%2 of 5
Next 30 trading days−0.6%2 of 5

For scale, GRFS’s typical 20-trading-day move in either direction is about 8.7%.

Grifols market cap and key statistics

Grifols’s market cap is $7.35B, with a P/E ratio of 10.5 and revenue of $7.60B over the last twelve months.

Valuation

Market cap
$7.35B
P/E ratio
10.5
Forward P/E
7.3
EPS, TTM
$0.83
Gekko Fair Value
$11.92

Trading

Volume
312,662
Avg volume, 20 days
752,397
52-week high
$9.77
52-week low
$6.96
Shares outstanding
258.2M

Financials

Revenue, TTM
$7.60B
Profit margin
6.4%
Return on equity
7.3%
Quarterly earnings growth, YoY
+32.9%

Risk and income

Beta
1.13
Typical daily move
±3.1%
Typical 20-day move
±8.7%

Grifols stock news this week

Coverage of Grifols this week reads positive: 2 positive, 1 neutral and 0 negative headlines.

News sentiment positive

More stocks

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Health technology

Grifols stock FAQ

What is Grifols’s market cap?

Grifols’s market cap is $7.35B at the Nov 13, 2026 close of $8.69, with 258.2M shares outstanding. The shares trade on a P/E ratio of 10.5.

What is the Grifols stock forecast?

The consensus analyst 12-month price target for Grifols is $10.37, +19.3% from the last close. Of the 1 firm that rated the stock in the last 90 days, 0 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Grifols stock overvalued or undervalued?

On Gekko’s estimate Grifols is undervalued: the Nov 13, 2026 close of $8.69 is 27.1% below Gekko Fair Value of $11.92. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Grifols report earnings next?

Grifols is expected to report on Mar 4, 2027 (109 days away). Analysts expect earnings of $0.33 per share on revenue of $2.31B. Grifols beat the earnings estimate in 1 of its last 8 reports, moving 5% on average across the report.

What is Grifols’s 52-week high and low?

Grifols’s 52-week high is $9.77 and its 52-week low is $6.96; it closed at $8.69 on Nov 13, 2026, 0.0% over the past year. Over the last five years the shares peaked at $13.34 on May 24, 2022.

Is Grifols stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and earnings risk), 2 as mixed (trend and gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Grifols the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.